158 related articles for article (PubMed ID: 34582263)
21. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
22. OtoID: new extended frequency, portable audiometer for ototoxicity monitoring.
Dille MF; Jacobs PG; Gordon SY; Helt WJ; McMillan GP
J Rehabil Res Dev; 2013; 50(7):997-1006. PubMed ID: 24301436
[TBL] [Abstract][Full Text] [Related]
23. Development and evaluation of a portable audiometer for high-frequency screening of hearing loss from ototoxicity in homes/clinics.
Jacobs PG; Silaski G; Wilmington D; Gordon S; Helt W; McMillan G; Fausti SA; Dille M
IEEE Trans Biomed Eng; 2012 Nov; 59(11):3097-103. PubMed ID: 22801480
[TBL] [Abstract][Full Text] [Related]
24. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Bass JK; Huang J; Onar-Thomas A; Chang KW; Bhagat SP; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Heath JA; McCowage G; Cohn RJ; Fisher MJ; Robinson G; Broniscer A; Gajjar A; Gurney JG
Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
[TBL] [Abstract][Full Text] [Related]
25. Perspectives and practices of ototoxicity monitoring.
Paken J; Govender CD; Pillay M; Sewram V
S Afr J Commun Disord; 2020 May; 67(1):e1-e10. PubMed ID: 32501032
[TBL] [Abstract][Full Text] [Related]
26. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.
Yancey A; Harris MS; Egbelakin A; Gilbert J; Pisoni DB; Renbarger J
Pediatr Blood Cancer; 2012 Jul; 59(1):144-8. PubMed ID: 22431292
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa.
Paken J; Govender CD; Pillay M; Feyasa M; Sewram V
PLoS One; 2023; 18(4):e0283639. PubMed ID: 37014872
[TBL] [Abstract][Full Text] [Related]
29. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
30. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
31. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
Dille MF; McMillan GP; Reavis KM; Jacobs P; Fausti SA; Konrad-Martin D
J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
[TBL] [Abstract][Full Text] [Related]
33. The current state of ototoxicity monitoring in New Zealand.
Steffens L; Venter K; O'Beirne GA; Kelly-Campbell R; Gibbs D; Bird P
N Z Med J; 2014 Jul; 127(1398):84-97. PubMed ID: 25146864
[TBL] [Abstract][Full Text] [Related]
34. Baseline audiological profiling of South African females with cervical cancer: an important attribute for assessing cisplatin-associated ototoxicity.
Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
BMC Womens Health; 2021 Apr; 21(1):164. PubMed ID: 33879158
[TBL] [Abstract][Full Text] [Related]
35. Ototoxicity monitoring in children treated with platinum chemotherapy.
Brooks B; Knight K
Int J Audiol; 2018 Sep; 57(sup4):S34-S40. PubMed ID: 28737048
[TBL] [Abstract][Full Text] [Related]
36. Practical grading system for evaluating cisplatin ototoxicity in children.
Chang KW; Chinosornvatana N
J Clin Oncol; 2010 Apr; 28(10):1788-95. PubMed ID: 20194861
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.
Stöhr W; Langer T; Kremers A; Bielack S; Lamprecht-Dinnesen A; Frey E; Beck JD;
Cancer Invest; 2005; 23(3):201-7. PubMed ID: 15945505
[TBL] [Abstract][Full Text] [Related]
38. A longitudinal community-based ototoxicity monitoring programme and treatment effects for drug-resistant tuberculosis treatment, Western Cape.
Stevenson LJ; Biagio-de Jager L; Graham MA; Swanepoel W
S Afr J Commun Disord; 2022 Mar; 69(1):e1-e13. PubMed ID: 35384675
[TBL] [Abstract][Full Text] [Related]
39. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
40. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
